New Delhi: The All India Syringe & Needle Manufacturers Association, the nodal body for domestic syringe manufacturers expressed disappointment over Government’s decision to restrict the export of syringes and said that it will put the domestic syringe makers in an awkward situation.
The Directorate General of Foreign Trade (DGFT) on 4th October issued a notification saying that the export policy for syringes with or without needles has been amended from “free” to “restricted”
The statement from AiSNMA read: “It takes lots of effort and years to build credibility as a global supplier and India’s reputation as Manufacturing Hub of Syringes will be tarnished as being undependable. We will always prioritize domestic needs”
Mr. Rajiv Nath, President, All India Syringes and Needles Manufacturers Association (AiSNMA) urged the Government to:
To lift the restriction on Non-covid sizes of syringes like Insulin syringes, 5 ml & larger syringe sizes or 0.3 ml AD syringes developed for Pfizer which can’t be used in India for vaccination and will be a wasted capacity otherwise.
At least 50% of the quantity shipped to a Country last year in October – January period of 0.5 ML / 1 ML / 2 ML & 3 ML may be allowed to be maintained. This will enable a historical past performance benchmark of standard needs to be catered to if rationing needs to be done
Clarity should be given of India’s quarterly needs by MoH&FW for calendar year 2022 as we can’t plan on 2-4 months window horizon basis